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The Streptococcus pyogenes NAD-glycohydrolase (SPN) is a toxic enzyme that is introduced into infected host cells by
the cytolysin-mediated translocation pathway. However, how S. pyogenes protects itself from the self-toxicity of SPN
had been unknown. In this report, we describe immunity factor for SPN (IFS), a novel endogenous inhibitor that is
essential for SPN expression. A small protein of 161 amino acids, IFS is localized in the bacterial cytoplasmic
compartment. IFS forms a stable complex with SPN at a 1:1 molar ratio and inhibits SPN’s NAD-glycohydrolase activity
by acting as a competitive inhibitor of its b-NAD
þ substrate. Mutational studies revealed that the gene for IFS is
essential for viability in those S. pyogenes strains that express an NAD-glycohydrolase activity. However, numerous
strains contain a truncated allele of ifs that is linked to an NAD-glycohydrolase deficient variant allele of spn.O f
practical concern, IFS allowed the normally toxic SPN to be produced in the heterologous host Escherichia coli to
facilitate its purification. To our knowledge, IFS is the first molecularly characterized endogenous inhibitor of a
bacterial b-NAD
þ consuming toxin and may contribute protective functions in the streptococci to afford SPN-mediated
pathogenesis.
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Introduction
Bacterial pathogens secrete a multitude of factors that are
utilized to advance the infectious process. Many of the
secreted factors exhibit an enzymatic activity that is directed
against host-speciﬁc targets or are activated by host-speciﬁc
functions. However, a few secreted enzymes are quite
promiscuous and have the ability to adversely affect both
the microbe and the host cell. Because of this potential self-
toxicity, bacteria must develop mechanisms to protect
themselves from the deleterious effects of these universally
toxic enzymes in order to successfully use them in patho-
genesis. One toxic enzyme, the secreted nicotinamide
adenine dinucleotide (NAD)–glycohydrolase of Streptococcus
pyogenes (SPN, also named NGA [1]), has recently been shown
to be injected into the host cell cytoplasm via a specialized
translocation process known as cytolysin-mediated trans-
location (CMT) [2,3]. However, how S. pyogenes manages the
potential self-toxicity of SPN is unknown.
SPN is one of several secreted toxins that are thought to
contribute to the pathogenesis of the numerous diseases that
S. pyogenes can cause. These range from superﬁcial (pharyng-
itis, impetigo) to life threatening (toxic shock syndrome,
necrotizing fasciitis) [4]. The contribution that any one toxin
makes to a speciﬁc S. pyogenes disease is generally not
understood. However, SPN has several activities that suggest
it may be important for pathogenesis. As an NAD-glycohy-
drolase, its most well characterized activity is its ability to
cleave b-NAD
þ at the ribose-nicotinamide bond to generate
ADP-ribose and the potent vasoactive compound nicotina-
mide [5 7]. Similar to several other NAD-glycohydrolases,
SPN has also been reported to have a cyclase activity capable
of converting b-NAD
þ into cyclic ADP-ribose, a potent
second messenger for calcium mobilization [8]. The observa-
tion that SPN can transfer ADP-ribose to certain synthetic
substrates has suggested that SPN may ADP-ribosylate an
important host protein in order to modify the function of
that protein [1]. However, the roles that any of these activities
may contribute to pathogenesis remains to be established.
Studies using in vitro models of streptococcal pathogenesis
have provided evidence that SPN can alter host cell behavior
following its translocation into the cytosolic compartment
[2,3]. One effect of intracellular SPN is an enhanced cytotoxic
response that results in the rapid death of the infected host
cell [2,3]. The basis of the cytotoxic response is not under-
stood; however, any of SPN’s enzymatic activities could
potentially have deleterious effects on host cell viability. For
example, if left unchecked, SPN’s robust NAD-glycohydrolase
activity would likely result in a signiﬁcant reduction in the
intracellular stores of b-NAD
þ. As a co-factor, b-NAD
þ is
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energy-producing biological reactions (for a recent review,
see [9]). Depletion of b-NAD
þ would be likely be toxic for
both the intoxicated host cell and the streptococcal cell
producing SPN. Toxicity for bacterial cells would explain the
fact that it has not been possible to clone and express the
intact gene for SPN in heterologous hosts such as Escherichia
coli (M. G. Caparon, unpublished data). Thus, successful
production of SPN by its native S. pyogenes host likely requires
some mechanism for management of its toxic properties.
In this report, we describe immunity factor for SPN (IFS), a
novel endogenous inhibitor of the NAD-glycohydrolase
activity of SPN. These studies show that the ability of S.
pyogenes to express and secrete an active SPN has an essential
dependence on the production of IFS in its cytoplasmic
compartment. Furthermore, co-expression of SPN and IFS
allows the normally toxic SPN to be produced at high levels in
E. coli and allows SPN to be exported as an active enzyme into
the periplasmic space. Fractionation of both recombinant
and streptococcal extracts identiﬁed a cytoplasmic inhibition
of NAD-glycohydrolase activity that was dependent on IFS.
The mechanism of inhibition involves the ability of IFS to
bind tightly to SPN and to act as a competitive inhibitor of its
b-NAD
þ substrate. Taken together, these data reveal how S.
pyogenes protects itself from the toxic effects of SPN through
its expression of IFS, a novel inhibitor of a b-NAD
þ consum-
ing microbial toxin.
Results
Efficient Cloning and Expression of SPN
The fact that it has not been possible to clone SPN in any E.
coli expression vector led us to hypothesize that S. pyogenes
must have a factor that protects it from any potential toxicity
associated with SPN. In searching for this putative factor, we
noted that the gene for SPN is present in an operon that
includes the gene encoding SLO, the pore-forming compo-
nent of the CMT injection pathway (Figure 1). Of interest, the
operon also includes an open reading frame (spy0166, Figure
1) that could potentially encode a small protein (161 amino
acids, 18.8 kDa) and would be negatively charged at neutral
pH (predicted pI ¼ 5.39). The Spy0166 protein lacks a gram-
positive Sec-dependent signal peptide (see Materials and
Methods) and would therefore likely serve its role as a soluble
cytoplasmic protein since the Sec pathway is the only
available route for protein export in S. pyogenes. These
properties are also characteristic of some protease inhibitors
[10,11] and chaperones of proteins translocated by the type
III secretion systems of gram-negative bacteria [12], both of
which can increase the efﬁciency of expression of their
partner proteins in E. coli and in their native hosts [13 16].
Based on these observations, we tested whether spy0166 from
S. pyogenes strain JRS4 could support the expression of spn in
E. coli when both genes were placed under the control of the
arabinose-inducible promoter on the vector pBAD/gIIIB (see
Materials and Methods). In this construct (pMAM3.18), the
native signal sequence of SPN was replaced with the gene III
signal sequence (for efﬁcient periplasmic targeting) while 6X-
HIS and c-myc epitope tags were grafted on the carboxy-
terminal end of Spy0166. Unlike any previous SPN expression
construct, pMAM3.18 efﬁciently transformed E. coli (.10
4
transformants/lg DNA) with high ﬁdelity (no nucleotide
substitutions, as determined by sequence analysis of several
clones). Furthermore, there was no loss of viability following
induction of the vector’s promoter and fractionation of the
resulting cultures revealed SPN in the periplasmic fraction
and Spy0166 in the cytoplasmic fraction as detected by
Western blot analysis (data not shown).
Spy0166 Inhibits the Glycohydrolase Activity of SPN
Since SPN’s b-NAD
þ consuming glycohydrolase activity
may have contributed to the protein’s apparent toxicity for E.
coli, it was of interest to determine whether Spy0166 could
inhibit SPN’s ability to cleave b-NAD
þ. The strategy was to
mix together periplasmic andc y t o p l a s m i cf r a c t i o n si n
various combinations following arabinose induction of E. coli
strains containing either pMAM3.18 or the vector alone.
Upon analysis, the periplasmic fractions derived from
pMAM3.18, but not vector-containing strains, demonstrated
a robust NAD-glycohydrolase activity (compare bars 1 and 2,
Figure 2). Furthermore, the activity produced by pMAM3.18
was not affected by mixing with the cytoplasmic fraction
derived from a strain containing the vector alone (bar 3,
Figure 2). In contrast, mixing an SPN-containing periplasmic
fraction with an Spy0166-containing cytoplasmic fraction
resulted in an inhibition of NAD-glycohydrolase activity to
near background levels (bar 4, Figure 2), and the degree of
inhibition was dependent upon the amount of Spy0166-
Figure 1. The spn-slo Operon Includes the Open Reading Frame spy0166
The figure depicts the spn-slo chromosomal operon from S. pyogenes M1
strain SF370 [18]. A promoter upstream of spn (bent arrow) drives
expression of spn and slo. Assignment of open reading frames is taken
from the annotation of the SF370 genome.
DOI: 10.1371/journal.ppat.0010035.g001
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Immunity Factor for SPN (IFS)
Synopsis
The gram-positive bacterium Streptococcus pyogenes is a human
pathogen that causes a wide range of infections from pharyngitis
(‘‘strep throat’’) to invasive necrotizing fasciitis (‘‘flesh-eating
disease’’). While strep throat responds to antibiotic therapy, more
invasive infections caused by S. pyogenes often require surgical
intervention. It is currently unknown exactly how the bacteria can
switch between the different types of infection, but one possibility is
via a mechanism by which the bacterium injects a bacterial protein
toxin (S. pyogenes NAD-glycohydrolase [SPN]) into human skin cells,
causing their death. In this study, the authors have shown that the
injected toxin also has the ability to affect the bacteria. A second
protein neutralizes SPN to ensure the bacteria are immune to its
toxic effects. Consequently, S. pyogenes has developed a valuable
weapon in its arsenal to promote its survival by ensuring the safe
production of SPN, through its own protection by immunity factor
for SPN, enabling the delivery of active SPN into human cells. The
process reported in this paper may ultimately help create
therapeutic inhibitors of SPN and possibly other SPN-like toxins
implicated in microbial disease progression.containing cytoplasmic extract mixed with SPN (Figure 3). In
the absence of SPN, Spy1066 had no glycohydrolase activity
of its own (bars 5, 6, and 7, Figure 2). Based on its ability to
inhibit NAD-glycohydrolase activity and support the viability
of SPN-expressing E. coli, Spy0166 was renamed IFS.
Two Alleles of spn and ifs
Comparison of spn operon sequences among the genomes
available for several S. pyogenes strains along with sequences
obtained from two other commonly studied strains (JRS4 [M6
serotype, 17] and HSC5 [M14 serotype, unpublished data])
revealed the presence of at least two distinct alleles of ifs.A
distinguishing characteristic is the presence of a nonsense
mutation that converts the codon encoding leucine at
position 24 (TAT) to a stop codon (TAA) (Figure 4). As a
result, the annotation of the genomes of SF370 [18] and
MGAS8232 [19] lists the codon for methionine at position 44
as the initiation codon of the IFS open reading frame (Figure
4). The strain used to characterize IFS in the experiments
described in the previous section contains the longer allele
(JRS4, Figure 4). In addition, it had been previously reported
that there are at least two distinct alleles of spn that differ by
ﬁve nonsynonymous substitutions [1]. There was a correlation
between which spn allele a given strain contained and whether
or not it produced immunoreactive SPN [1]. Of the strains
analyzed in this study, JRS4 is known to produce active SPN
[2] and has the allele associated with active expression (JRS4-
WT, Figure 5). Furthermore, the NAD-glycohydrolase activity
produced by this strain is completely dependent upon SPN
(SPN
 , Figure 5). In contrast, HSC5 has the allele that was
associated with the absence of an ability to produce a
detectable SPN protein similar to that reported for M1 strain
SF370 [1]. As predicted by this comparison, HSC5 failed to
produce any detectable NAD-glycohydrolase activity and any
immunoreactive SPN protein (compare HSC5-WT and SF370,
Figure 5). One difference between JRS4, SF370, and HSC5 is
that the latter two strains are strong producers of the SpeB
cysteine protease, while the former is not. Since it has been
reported that SpeB can completely degrade SPN [20], HSC59s
ability to produce SPN was examined in the presence of the
cysteine protease inhibitor E64. With this treatment, HSC5
now contained the SPN protein at levels similar to JRS4
(compare JRS4-WT and HSC5-E64, Figure 5). However, the
HSC5 SPN still lacked any detectable NAD-glycohydrolase
Figure 2. SPN Activity Is Inhibited by IFS (Spy0166)
The labeled bars indicate the NAD-glycohydrolase activities of mixtures of isolated periplasm (as a source of SPN) and cytoplasm (as a source of
Spy0166) from various E. coli strains containing the plasmids indicated. The presence (þ) or absence ( ) of either SPN or Spy0166 in a particular
periplasmic or cytoplasmic extract is indicated. Vector is pBAD/gIIIB containing no inserted streptococcal DNA. Asterisk indicates that the level of NAD-
glycohydrolase activity was below the limit of detection of 50 pmol/min. Due to its ability to inhibit NAD-glycohydrolase activity, Spy0166 was renamed
IFS. Data represent the mean 6 standard error of the mean derived from three independent experiments.
DOI: 10.1371/journal.ppat.0010035.g002
Figure 3. Dose-Dependent Inhibition by IFS
NAD-glycohydrolase activity produced by a constant concentration of
periplasmic extract (as a source of SPN) mixed with increasing
concentrations of a cytoplasmic extract (as a source of IFS), both of
which were prepared from TOP10(pMAM3.18). Asterisk indicates that the
level of NAD-glycohydrolase activity was below the limit of detection of
50 pmol/min. Data represent the mean 6 standard error of the mean
derived from three independent experiments.
DOI: 10.1371/journal.ppat.0010035.g003
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Immunity Factor for SPN (IFS)activity (HSC5-E64, Figure 5). This was not a result of E64
treatment or any other inhibitory factor in HSC5 super-
natants, because (1) E64 did not inhibit JRS4 SPN (data not
shown), (2) elimination of protease activity through mutation
of SpeB’s active site residue or a deletion of an essential
activator of speB transcription allowed HSC5 to produce SPN
that still exhibited no detectable NAD-glycohydrolase activity
(HSC5-C192S and HSC5-RopB
 , Figure 5), and (3) mixing
HSC5 and JSR4 supernatants did not result in inhibition of
the JRS4 SPN (data not shown). Consistent with a previous
report [20], strain SF370 produced a low amount of SPN in
the presence of E64 by Western blot analysis with no
detectable NAD-glycohydrolase activity (data not shown).
Taken together, these data indicate that in addition to
possessing two alleles for ifs, the streptococcal population
contains at least two major alleles of spn, and the product of
one of these lacks detectable NAD-glycohydrolase activity.
Cytoplasmic Extracts of S. pyogenes Contain an Allele-
Dependent Inhibitory Activity
The data presented above suggest that the function of IFS
is to inhibit the NAD-glycohydrolase activity of SPN in the
cytoplasmic compartment of S. pyogenes. In addition, available
data indicate linkage between spn and ifs alleles. Strains that
contain the spn allele associated with activity (e.g., JRS4)
contain the larger ifs open reading frame [see also MGAS315
genome, 21], while those that possess the spn allele that does
not express activity (e.g., HSC5, SF370) have truncated ifs [see
also MGAS8232 genome, 19]. To directly test whether S.
pyogenes contains an inhibitory activity for SPN and the
possible inﬂuence of the ifs allele, the ability of cytoplasmic
extracts from various strains to inhibit NAD-glycohydrolase
activity was evaluated. Consistent with the behavior of IFS
cloned from JRS4 (see above), cytoplasmic extracts of JRS4
contained an activity that inhibited the NAD-glycohydrolase
Figure 4. Two Alleles of ifs
A multiple alignment of ifs from several S. pyogenes strains is shown. A nonsense mutation in the codon for leucine 24 (indicated by asterisk) produces a
truncated ifs open reading frame in several strains. The circles above the sequence show the position of several other polymorphic residues. The ifs loci
were taken from the following genomes: M1 (SF370, ifs ¼ Spy0166), M13 (MGAS315, ifs ¼ Spy_M30129), M18 (MGAS8232, ifs ¼ Spy_M180164), and
strains JRS4 and HSC5.
DOI: 10.1371/journal.ppat.0010035.g004
Figure 5. Expression of Enzymatically Active and Inactive SPN Proteins
A Western blot analysis of cell-free culture supernatant fluids from various S. pyogenes strains is shown. The blot was developed with an antiserum that
recognizes the proteins indicated on the left, including SPN, full-length SLO, and a truncated form of SLO (SLO*) generated through a specific cleavage
by the streptococcal SpeB cysteine protease [52]. The lanes labeled under JRS4 include JRS4 itself (WT), SPN mutant SPN1 (SPN
 ), and SLO mutant SLO1
(SLO
 ), and under SF370, SF370 itself (WT). Lanes under HSC5 include HSC5 itself (WT), HSC5 grown in the presence of the protease inhibitor E64 (E64),
and mutants of HSC5: catalytically deficient SpeB mutant JWR10 (C192S) and protease regulatory mutant MNN100 (RopB
 ). The NAD-glycohydrolase
activity titer (NADase titer) of each supernatant fluid is shown at the bottom of each lane. The data shown are representative of results from three
independent experiments.
DOI: 10.1371/journal.ppat.0010035.g005
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Immunity Factor for SPN (IFS)activity of the secreted form of JRS4 SPN (Figure 6). In
contrast, cytoplasmic extracts from either HSC5 or SF370 did
not contain an activity that inhibited the NAD-glycohydro-
lase activity of JRS4 SPN (Figure 6). Extracts prepared from
HSC5 lacked activity even when prepared in the presence of
the protease inhibitor E64 (data not shown).
Cytoplasmic Inhibitory Activity Was Dependent on IFS
To determine if the inhibitory activity detected in JRS4
was due to IFS, an attempt was made to construct an in-
frame deletion in the gene for IFS. The method for
mutagenesis proceeds via the generation of a tandem
duplication of mutant and wild-type alleles in the genome
that can resolve to either allele by recombination. Typically,
chromosomes with either allele are isolated at similar
frequencies among the progeny [22]. However, while it was
possible to produce the merodiploid intermediate strain at
the ifs locus, all progeny recovered following resolution of
the duplication contained a copy of the wild-type allele (30 of
30 tested). In contrast, when mutagenesis was conducted in a
JRS4 SPN
  mutant, progeny with the mutant or wild-type ifs
alleles were recovered at equal frequencies (four mutants,
four wild-type, eight tested). These data suggest that IFS is
essential for viability when SPN is encoded in the genome.
Consistent with this, when progeny of the SPN
  mutant were
analyzed, only those progeny with the wild-type ifs allele
could inhibit SPN NAD-glycohydrolase activity (compare
IFS
þ Rev. to IFS
 , Figure 7). Inhibitory activity was restored
in the IFS
  mutant upon the introduction of an HA-tagged
version of the JRS4 ifs on a plasmid (compare pIFS-HA to
Vector, Figure 7). The presence of IFS in the cytoplasm of
the complementing strain was veriﬁed by Western blot
analysis using antiserum to the HA epitope tag (data not
shown). Taken together, these data indicate that in the
absence of IFS, expression of SPN is likely lethal for JRS4 and
that the inhibitory activity detected in cytoplasmic extracts is
dependent on IFS.
An SPN-IFS Complex
The ability of IFS to inhibit SPN’s enzymatic activity
suggested that the two proteins interact. To test this, pull-
down assays were conducted following mixing periplasmic
extracts (as a source of SPN) and cytoplasmic extracts (as a
source of IFS) prepared from various E. coli strains. In the ﬁrst
assay, the cytoplasmic extract was prepared from a strain
expressing IFS with C-terminal 6X-His and c-myc epitope
tags (IFS-H) and periplasm was prepared from a strain
expressing SPN and IFS. Following mixing, IFS-H was isolated
via selective binding to Ni-NTA agarose and any co-isolation
of SPN assessed by Western blot analysis. In the absence of
IFS-H, SPN demonstrated some afﬁnity for Ni-NTA agarose
under these conditions (lane 3, Figure 8A). However, in the
presence of IFS-H, SPN was readily co-isolated (lane 4, Figure
8A) at levels substantially greater than background observed
with cytoplasmic extracts from strains containing the vector
alone (lane 5, Figure 8A) or an irrelevant 6X-His–tagged
protein (lane 6, Figure 8A). The reciprocal experiment
yielded similar results, where IFS (without a 6X-His tag) was
selectively co-isolated only when incubated with periplasm
containing 6X-His–tagged SPN (SPN-H) (lane 4, Figure 8B)
and not in the absence of any periplasmic extract (lane 3,
Figure 8B), the presence of periplasmic extracts prepared
from strains expressing the plasmid vector alone (lane 5,
Figure 8B), or an irrelevant 6X-His–tagged protein (lane 6,
Figure 8B).
Figure 6. A Cytoplasmic Inhibitory Activity
The NAD-glycohydrolase activities of a mixture of JRS4 supernatant (as a
source of SPN) and cytoplasmic extracts prepared from the indicated
strains are shown. Asterisk indicates that the level of NAD-glycohydrolase
activity was below the limit of detection of 50 pmol/min. Data represent
the mean 6 standard error of the mean derived from three independent
experiments.
DOI: 10.1371/journal.ppat.0010035.g006
Figure 7. Inhibitory Activity Is Due to IFS
The NAD-glycohydrolase activities of a mixture of JRS4 supernatant (as a
source of SPN) and cytoplasmic extracts prepared from several
derivatives of JRS4 SPN
  mutant SPN1 are shown. Lanes include SPN
 
mutant itself (Parent), a derivative of SPN
  mutant with an in-frame
deletion in ifs (IFS
 ), a sibling of the SPN
  IFS
  deletion mutant that
reverted to wild-type ifs (IFS
þ Rev.), the SPN
  IFS
  deletion mutant
containing a plasmid-encoded HA-tagged version of IFS (IFS
  pIFS-HA),
and the pABG5 plasmid vector lacking ifs (IFS
  Vector). Asterisk indicates
that the level of NAD-glycohydrolase activity was below the limit of
detection of 50 pmol/min. Data represent the mean 6 standard error of
the mean derived from three independent experiments.
DOI: 10.1371/journal.ppat.0010035.g007
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Immunity Factor for SPN (IFS)Characteristics of the SPN-IFS Complex
The ability of IFS and SPN to form a complex was also
assessed by size exclusion chromatography. Analysis of
puriﬁed recombinant SPN (see Materials and Methods) by
this method indicated an apparent molecular weight in
solution of 52.4 6 1.5 kDa (Figure 9), consistent with the
predicted monomer size of the mature protein based on its
primary sequence (48.4 kDa) and several previous reports
indicating that SPN puriﬁed from streptococcal supernatant
ﬂuids is a monomer in solution [7,23,24]. However, a similar
analysis of puriﬁed recombinant IFS (see Materials and
Methods) indicated an apparent molecular weight of 31.5 6
3.2 kDa (Figure 9), a value that was unexpected based on a
molecular weight of 22.0 kDa predicted from the IFS-myc-HIS
primary sequence. This suggests that IFS exists as a monomer
with an extended shape or as an atypical dimer with Stoke’s
radius typical of a 31-kDa globular protein. Next, an
assembled SPN-IFS complex was puriﬁed from the cytoplasm
of recombinant E. coli (TOP10 strain harboring pMAM3.18)
and subjected to chromatography with the resulting size of
67.6 6 3.2 kDa (Figure 9) that was larger that either SPN or IFS
alone. Importantly, this complex eluted in a resolving fraction
that followed the void volume, which was calculated at 78.6
kDa (see Materials and Methods). Assembly of complex in vitro
from puriﬁed IFS and SPN resulted in a major peak eluting in
the void volume, indicating a possible aggregation event
occurred in vitro (data curve not shown). The size of the more
physiologically relevant in vivo assembled complex (67 kDa)
indicates that one SPN molecule (48 kDa) interacts with one
IFS molecule (22 kDa). This was conﬁrmed by an SDS-PAGE
analysis of several fractions obtained from the leading edge of
the high molecular peak that revealed the presence of both
SPN and IFS (Figure 10). Analysis of SDS-PAGE gels by
densitometry with comparison to known concentrations of
puriﬁed SPN and IFS indicated that the molar ratio of SPN to
IFS was 1:1 in these complexes, in agreement with the gel
ﬁltration data as stated above.
Figure 8. SPN and IFS Form a Complex
Ni-NTA pull-down assays detect the formation of a complex between IFS
and SPN.
(A) Periplasmic extracts (periplasm) from E. coli strain TOP10(pMAM3.8)
expressing an non 6X-His–tagged version of SPN (SPN), the pBAD/pIIIB
vector (Vec.), or buffer (None) were mixed with cytoplasmic extracts
(cytoplasm) from TOP10(pMAM3.19) that expressed a 6X-His and c-myc–
tagged version of IFS (IFS-H), the pBAD/gIIIB vector (Vec.), a plasmid
expressing a 6X-His and c-myc–tagged calmodulin (Cal-H), or buffer
(None). Proteins released following pull-down with Ni-NTA agarose were
analyzed by Western blot with an antiserum to detect SPN, as shown.
(B) Periplasmic extracts from TOP10(pMAM3.18) expressing a strain a 6X-
His–tagged version of SPN (SPN-H) were mixed with cytoplasmic extracts
prepared from TOP10(pMAM3.21), which expresses IFS with a c-myc
epitope, but lacking a 6X-His tag. Other designations are as in (A).
Proteins released following pull-down with Ni-NTA agarose were
analyzed by Western blot with an antiserum to detect the c-myc tags
of IFS and Cal-H, as shown. Controls are purified IFS and SPN that were
not subjected to pull-down, and the migration of IFS, SPN, and Cal-H is
indicated to the right.
DOI: 10.1371/journal.ppat.0010035.g008
Figure 9. Gel Filtration Chromatography of SPN, IFS, and the SPN-IFS
Complex
Purified SPN (B), IFS (C), or the SPN-IFS (A) complex was subjected to gel
filtration chromatography over Superdex 75 HR 10/30, and their elution
profiles are overlaid. Based on the elution of several standards (identities
of the standards are shown, and their elution volumes are indicated by
the corresponding arrows), the calculated molecular weights of SPN, IFS,
and the complex are 52.4 6 1.5, 31.5 6 3.2, and 67.6 6 3.2 kDa,
respectively. These calculations were based on the average elution
volumes derived from at least three independent column applications.
DOI: 10.1371/journal.ppat.0010035.g009
Figure 10. Analysis of the SPN-IFS Complex
Several fractions of the high-molecular-weight peak arising from gel
filtration chromatography of an SPN-IFS complex were analyzed by SDS-
PAGE as shown. Purified SPN and IFS are included for comparison.
Densitometric analyses (see Materials and Methods) of similar gels
containing known concentrations of purified SPN and IFS revealed a 1:1
molar stoichiometry of SPN to IFS in the complex.
DOI: 10.1371/journal.ppat.0010035.g010
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Immunity Factor for SPN (IFS)IFS Is a Competitive Inhibitor of SPN
In order to determine the inhibition mechanism, the
effects of IFS on the rate of hydrolysis of b-NAD
þ by SPN
were studied as a function of IFS concentration (Figure 11).
The rate of b-NAD
þ hydrolysis in the absence of IFS showed a
hyperbolic increase with an apparent Km for b-NAD
þ of 379
6 74 lM and an observed Vmax of 9.9 6 1.2 lM/min.
Inhibition of SPN activity by IFS was determined by varying
the concentration of IFS in the reactions. Increasing
concentrations of IFS decreased the rate of b-NAD
þ
hydrolysis. Simultaneous ﬁtting of these curves by a com-
petitive model yielded a Km,app of 348 6 54 lM for b-NAD
þ,a
Vmax,obs of 9.6 6 0.8 lM/min, and a KI,app of 2.0 6 0.3 nM
(Figure 11). The observed Km,app and Vmax,obs values were
consistent to those obtained by ﬁtting of the data by the
Michaelis-Menten equation in the absence of any inhibitor.
Simultaneous ﬁtting of the curves by uncompetitive and
noncompetitive models yielded parameters that ﬁt the data
poorly (ﬁts not shown) and were inconsistent to the
parameters obtained by ﬁts of b-NAD
þ hydrolysis in the
absence of any inhibitor. The results demonstrate that SPN
was inhibited by IFS in a competitive manner as indicated by
the consistent Michaelis constants. The results also indicated
that the complex between SPN and IFS was tight in
comparison with the substrate b-NAD
þ.
Discussion
In this study, we have described IFS, a novel endogenous
inhibitor of SPN, the secreted NAD-glycohydrolase of S.
pyogenes. IFS forms a stable complex with active SPN and
functions as a competitive inhibitor of its b-NAD
þ substrate.
Furthermore, IFS proved to be essential for the ability of S.
pyogenes to express SPN. As a practical consequence, co-
expression of IFS and SPN proved to be a highly successful
strategy for production of SPN in E. coli. To our knowledge, ifs
represents the ﬁrst molecularly characterized gene product
encoding an endogenous inhibitor for a b-NAD
þ consuming
microbial toxin or for any NAD-glycohydrolase to date from
either the prokaryotic or eukaryotic kingdoms.
In order to produce and secrete universally toxic mole-
cules, bacterial pathogens have evolved several strategies to
protect themselves from the self-toxicity of these molecules.
For example, some toxins, like the calmodulin-dependent
adenylate cyclases or the cholesterol-dependent cytolysins,
require a co-factor found exclusively in a host compartment
for activity (for reviews, see [25,26]). Other toxic enzymes,
most notably broad-spectrum proteases, are secreted as
inactive precursors whose conversion to an active form can
be subsequently regulated both temporally and spatially [27].
A less common strategy involves the production of a
cytoplasmic inhibitor. Although an inhibitor of the strepto-
coccal SpeB cysteine protease was recently discovered [28],
the best-studied example of this class is the staphostatin-
staphopain system of the staphylococci [29]. Staphopains are
secreted cysteine proteases that are speciﬁcally inhibited by
the staphostatins, which are small (approximately 13 kDa) and
acidic proteins that, similar to IFS, reside in the staph-
ylococcal cytoplasm. Also like IFS, the staphostatins form a
stable noncovalent complex at a 1:1 molar ratio with their
cognate staphopain in their fully folded and active con-
formations [30]. Three-dimensional structures of the staphos-
tatin-staphopain complex have revealed a competitive
mechanism of inhibition whereby the staphostatin binds to
the staphopain in a substrate-like manner forming a long-
lived inhibitor-enzyme complex [30 34]. The observations
that co-expression of a staphostatin increases the efﬁciency of
staphopain production when expressed in E. coli [13] and that
deletion of a staphostatin has a profound affect on the ability
of the mutant to produce its cell wall and export proteins [35]
have suggested that the function of the staphostatins is to
prevent improper degradation of cytoplasmic proteins by
premature activation of staphopains in the cytoplasmic
compartment.
Similar to a staphostatin, the function of IFS may prevent
the premature activation of the enzyme in the bacterial
cytosolic compartment. However, while numerous inhibitors
for various proteases have been described, including a recent
discovery of an SpeB endogenous inhibitor [28], endogenous
inhibitors of b-NAD
þ consuming toxins are less common.
Several prior reports have characterized endogenous NAD-
glycohydrolase inhibitory activity in extracts of Bacillus subtilis
and Mycobacterium phlei extracts [36,37]. However, identiﬁca-
tion of the genes that encode these activities has not been
reported. The ability of IFS to bind in a tight complex with a
1:1 molar stoichiometry with SPN and to act as a competitive
inhibitor of SPN’s b-NAD
þ substrate implies that IFS may
function similarly to the staphostatins and form a complex
that makes contact with residues at or near the catalytic
center of SPN. Alternatively, IFS may act as an effective
molecular mimic of b-NAD
þ and function as a noncleavable
substrate. Should the latter mechanism prove to be the case,
IFS may act as a broad-spectrum inhibitor of b-
NAD
þ consuming toxins.
An important and unusual feature of both IFS and the
staphostatins is that they are located in the cytoplasmic
compartment, yet they bind and inhibit the activities of their
Figure 11. Kinetic Analysis of the Inhibition Mechanism of SPN by IFS
The observed initial rate (vobs) of proteolysis of b-NAD
þ by SPN (0.125 U/
ml) was assessed in the absence ( ) and presence of varying
concentrations of IFS (*, 0.47 nM; m, 0.93 nM; D, 1.3 nM; &, 1.9 nM; &,
2.3 nM). The lines represent the nonlinear least-squares analysis of the
competitive inhibition model with the parameters described in the text.
Initial rates were measured, and the data were analyzed as described in
Materials and Methods.
DOI: 10.1371/journal.ppat.0010035.g011
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folded conformations. While this property is valuable if the
primary function of these proteins to inhibit the potentially
toxic activities of the prematurely activated toxins, it also
implies that these proteins become folded prior to their
secretion. In this scenario, IFS may act to protect the cell
from a small population of SPN molecules that drift off the
Sec secretion pathway and then fold in the cytoplasmic
compartment. This would explain why IFS is essential in both
native and heterologous hosts that contain NAD-glycohydro-
lase proﬁcient SPN. This function would also be consistent
with the apparent linkage between the NAD-glycohydrola-
se deﬁcient spn allele and the truncated allele for ifs. These
strains produced an SPN polypeptide but lacked a cytoplas-
mic inhibitory activity. Thus, in the absence of enzymatic
activity, an IFS-mediated inhibitory activity is not required,
and this would likely reduce any selective pressure to
maintain the full-length ifs allele. The loss of inhibitory
activity does not rule out the possibility that IFS may have
some other essential role. Multiple functions have been
attributed to the chaperones of the type III secretion
pathway, including secretion targeting of the effector-
chaperone complex, unfolding cognate effectors, protection
of effectors from proteases, and establishing a temporal
hierarchy for effector secretion [38]. Many of these same
functions are likely required for successful targeting for Sec
pathway secretion and delivery of SPN to the CMT pathway.
Thus, any of these functions may also be provided by IFS.
However, it remains to be determined whether the truncated
allele is expressed and whether it is required for expression of
the NAD-glycohydrolase deﬁcient SPN or its translocation
into the host cell cytosol via CMT.
The existence of an NAD-glycohydrolase deﬁcient allele of
spn raises some interesting questions on the function of SPN
and its repertory of enzymatic activities in pathogenesis. An
important role is supported by the fact that several studies
have shown that the gene for SPN is present in virtually all S.
pyogenes isolates examined to date [1,39]. Two major alleles of
spn were found, and there was an associated lack of
immunoreactive protein for one allele [1]. We have shown
here that the lack of detectable protein is directly caused by
an SpeB-dependent degradation event through the use of a
biochemical inhibitor and mutagenesis of speB (see Figure 5),
and this observation was also noted in a recent study [20]. It is
unclear if the variability in detectable SPN protein is due to
an alteration in SpeB expression or whether SpeB is
inefﬁcient at degrading the active SPN allele. Furthermore,
we have demonstrated an association of the spn allele
exhibiting NAD-glycohydrolase activity with a full-length ifs
allele. Due to the small sampling of strains used in this study,
a more thorough study on the correlation of these alleles
could be useful to establish whether the ifs nonsense mutation
induces a resulting mutation in spn to prevent self-toxicity by
b-NAD
þ depletion. Nevertheless, the fact that the NAD-
glycohydrolase deﬁcient allele is apparently widely distrib-
uted in the streptococcal population indicates it may have an
as-yet-unidentiﬁed contribution to pathogenesis that is
independent of an NAD-glycohydrolase activity. Thus, a
more thorough understanding of SPN’s activities and its
contribution to virulence via the CMT pathway will require
considerably more experimentation.
Materials and Methods
Bacterial strains and culture conditions. Molecular cloning experi-
ments utilized E. coli TOP10 (Invitrogen, Carlsbad, California, United
States). The S. pyogenes strains JRS4, SLO1 (JRS4 SLO
 ), SPN1 (JRS4
SPN
 ), SF370, HSC5, JWR10 (HSC5 speBC192S), and MNN100 (HSC5
RopB
 ) have previously described [2,40 42]. Luria-Bertaini medium
was used for culture of E. coli, while routine culture of S. pyogenes
utilized Todd-Hewitt medium (BBL) supplemented with 0.2% yeast
extract (Difco, BD Biosciences, San Diego, California, United States)
(THY medium). For certain assays (see below), S. pyogenes was cultured
in Dulbecco’s modiﬁed Eagle media (without glucose, phenol red, or
pyruvate) supplemented with 2.5% yeast extract and 2% glucose
(DMEM-YE medium). Antibiotics were routinely used to maintain
selection for plasmids and were added to media at the following
concentrations: kanamycin, 50 lg/ml for E. coli and 500 lg/ml for S.
pyogenes; erythromycin, 750 lg/ml for E. coli and 1 lg/ml for S. pyogenes;
and ampicillin, 100 lg/ml for E. coli. Where indicated, the cysteine
protease inhibitor E-64 (Sigma, St. Louis, Missouri, United States) was
added to THY medium at a ﬁnal concentration of 28 lM.
DNA and computational techniques. Plasmid DNA was isolated by
standard techniques and used to transform chemically competent E.
coli [43] and to transform S. pyogenes by electroporation [44].
Restriction endonucleases, ligases, and polymerases were used
according to the manufacturers’ recommendations. Chromosomal
DNA was puriﬁed from S. pyogenes as previously described [44].
Fidelity of all DNA sequences generated by PCR was veriﬁed using
ﬂuorescently labeled dideoxynucleotides (Big Dye terminators;
Applied Biosystems, Foster City, California, United States) and the
appropriate oligonucleotide primers in DNA sequencing reactions
according to the recommendations of the manufacturer. Identiﬁca-
tion of gram-positive secretion signal peptides utilized the SignalP
model [45]. The alignment of spy0166 (ifs) open-reading frames was
generated using the ClustalW algorithm [46].
Cloning and expression of spn and ifs. Plasmids for the cloning and
expression of spn and ifs in E. coli were based on the pBAD/gIIIB
expression vector (Invitrogen). Primers MAM98 and MAM84 (Table
S1) were designed to amplify a single fragment containing spn and ifs
from JRS4 chromosomal DNA so that the sequences encoding the
signal sequence of spn were replaced with a sequence encoding a 6X-
His afﬁnity tag. The fragment was digested with NcoI and BstBI using
sites embedded in the primers and inserted between the NcoI and
BstBI sites of pBAD/gIIIB. In the resulting plasmid (pMAM3.14), spn
was grafted in-frame with a gene III signal sequence followed by the
6X-His sequence and ifs was grafted in-frame with vector sequences
specifying a C-terminal c-myc epitope tag followed by a 6X-His
afﬁnity tag. A derivative of pMAM3.14 was constructed with primers
MAM101 and MAM102 (Table S1) using an ‘‘inside-out’’ PCR strategy
[47] in order to remove the 6X-His segment introduced into ifs. The
resulting plasmid (pMAM3.18) contains an additional PstI site
introduced by the primers that was used to recircularize the PCR
product. A similar strategy using primers MAM93B and MAM84
(Table S1) and a pMAM3.14 template was used to construct a plasmid
(pMAM3.8) that lacked the segment encoding the 6X-His tag
upstream of spn, while retaining the 6X-His tag sequence on ifs.
Primers MAM103 and MAM84 (Table S1) were used to amplify and
insert ifs between the NcoI and BstB1 sites of pBAD/gIIIB. The
resulting plasmid (pMAM3.19) expressed IFS with C-terminal c-myc
and 6X-His tags in the cytoplasmic compartment of its E. coli host.
This plasmid was modiﬁed to remove the sequence encoding the 6X-
His tag with primers MAM101 and MAM102 using an ‘‘inside-out’’
strategy as described above. The resulting plasmid (pMAM3.21)
expresses IFS with a c-myc epitope tag.
Construction of ifs in-frame deletion. Primers MAM78B and
MAM79B (Table S1) ampliﬁed a 1.4-kb fragment containing the
entire JRS4 ifs open reading frame with ﬂanking sequences in spn and
slo. The fragment was inserted into a standard vector (pCRII;
Invitrogen) using XhoI sites embedded in the primers. An ‘‘inside-
out’’ PCR strategy using primers MAM80 and MAM81 (Table S1)
introduced an in-frame deletion of 0.46 kb into the ifs open-reading
frame. Sites for SalI (embedded in primers MAM80 and MAM81) were
used to insert the fragment containing the deletion and ﬂanking
sequences into the shuttle vector pJRS233 [48]. The resulting plasmid
(pMAM3.3) was then used in attempts to replace the wild-type ifs
allele as described in the text according to a previously described
method [42]. Wild-type and mutant alleles were distinguished by PCR
ampliﬁcation of chromosomal DNA using primers MAM79B and
MAM87S (Table S1) that yielded products of 1,083 bp (wild-type) or
627 bp (ifs deletion), and assignment was conﬁrmed by PCR using
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product only in the presence of wild-type ifs.
Ectopic expression of ifs in S. pyogenes. Primers MAM108 and
MAM112 (Table S1) were used to amplify ifs with its native ribosome-
binding site from JRS4 chromosomal DNA with the addition of DNA
encoding a C-terminal HA epitope tag. The resulting 0.51-kb
fragment was inserted between the EcoRI and PstI of the E. coli/
streptococcal shuttle vector pABG5 [49] using sites embedded in the
primers. In the resulting plasmid (pMAM3.32), expression of the gene
for the modiﬁed IFS (IFS-HA) is controlled by the rofA promoter [49].
Expression of IFS-HA following introduction of pMAM3.32 into S.
pyogenes was conﬁrmed in Western blot analysis of cell extracts (see
below) using an anti-HA antiserum (Sigma).
Assays for SPN. Expression of SPN protein was evaluated by
Western blot analyses of S. pyogenes culture supernatant ﬂuids [2] or
from E. coli periplasmic or cytoplasmic fractions [50] using an
antiserum that cross-reacts with SPN (anti-SLO antibody, lot No.
7317011; Golden West Biologicals, Temecula, California, United
States) [2]. The NAD-glycohydrolase activity of SPN was assessed by
either endpoint titer or determination of units of activity (in
picomoles of b-NAD
þ cleaved per minute), both as previously
described [2]. For the latter, more than 50 units represents the lower
limit of detection of the assay.
Assays for IFS. ExpressionofSPNproteinwasevaluatedbyWestern
blot analyses of cytoplasmic extracts of S. pyogenes or from periplasmic
or cytoplasmic fractions [50] of E. coli using antisera that recognize the
appropriate HA (see above) or c-myc (Sigma) epitope tags. To isolate
streptococcal cytoplasmic extracts, bacterial cells (washed twice and
resuspended in 10 mM Tris [pH 8.0]) were lysed using a high-speed
reciprocating shaking device (FP-120; Savant Instruments, Holbrook,
New York, United States), and the extract was separated by
centrifugation (15,0003g, 10 min, 4 8C). The success of streptococcal
cell lysis was veriﬁed by visualization of cytoplasmic proteins by SDS-
PAGE analysis and supported by the gain of inhibitory activity in the
complemented ifs
  mutant strain. Activity assays for the ability of IFS
to inhibit NAD-glycohydrolase activity were as follows. For E. coli
fractions, equal volumes of induced periplasm (0.05 lg total protein),
cytoplasm (0.5 lg total protein), or buffer (13 PBS) were mixed
and incubated with b-NAD
þ (0.133 lM) for 0 to 50 min in a 96-well
microtiter plate. For S. pyogenes fractions, cell-free overnight culture
supernatants from JRS4 (diluted 1:15 in PBS) were mixed with
streptococcal cytoplasmic extracts (50 lg total protein) or buffer (13
PBS) and incubated with b-NAD
þ as described above. Units of NAD-
glycohydrolase activity detectable at the end of the incubation period
were then determined as described previously [2].
Ni-NTA agarose pull-down assay. The various E. coli strains
described in the text were cultured under inducing conditions (see
below), and cytoplasmic and periplasmic fractions were prepared
[50]. For pull-down assays, periplasm (7.5 lg total protein), cytoplasm
(75 lg total protein), or buffer (13PBS) was coincubated for 15 min at
room temperature prior to the addition of 50 ll of a 50% solution of
Ni-NTA agarose (Qiagen, Valencia, California, United States). The
mixtures were incubated for an additional 15 min at room temper-
ature, and the agarose beads were recovered by centrifugation.
Following aspiration of the supernatant ﬂuids, the beads were washed
three times in an equal volume of wash buffer (50 mM NaH2PO4, 300
mM NaCl, 20 mM imidazole [pH 8.0]), and bound proteins were
eluted by incubation with an equal volume of elution buffer (50 mM
NaH2PO4, 300 mM NaCl, 250 mM imidazole [pH 8.0]) for 15 min at
room temperature. Beads were removed by centrifugation, and
proteins in the supernatant ﬂuids were subjected to Western blot
analyses using antisera to detect SPN or IFS. Controls included
extracts prepared from E. coli strains containing the vector alone
(pBAD/gIIIB) or pBAD/gIII/calmodulin (pCALM), which expresses
calmodulin with 6X-His and c-myc tags (Invitrogen).
Puriﬁcation of SPN. TOP10 cells containing pMAM3.18 were
induced at mid-log phase (OD600 0.5) for 4 h using 0.2% L-arabinose
(ﬁnal concentration). Periplasm was isolated as previously described
[50] and dialyzed against buffer composed of 50 mM phosphate buffer
and 300 mM NaCl (pH 7.0). The sample was then subjected to metal-
afﬁnity chromatography over a TALON Superﬂow resin using the
washing and elution conditions recommended by the manufacturer
(BD Biosciences). Fractions containing SPN were dialyzed in a buffer
containing20mMMES(pH5.8)andsubjectedtochromatographyover
a Resource S ion-exchange column (Amersham Biosciences, Little
Chalfont, United Kingdom) using a linear NaCl gradient (0 to 500 mM)
to elute SPN. Fractions were analyzed by SDS-PAGE, and those
fractionscontaininggreaterthan95%SPNwerepooled(seeFigure10).
Puriﬁcation of IFS. TOP10 cells containing pMAM3.19 were
induced at mid-log phase (OD600 0.5) for 4 h using 0.2% L-arabinose
(ﬁnal concentration). Cells were prepared by extraction of periplasm
and then resuspended in TALON column buffer (300 mM NaCl, 50
mM Na-phosphate [pH 7.0]) and lysed by sonication. The lysate was
then subjected to metal afﬁnity chromatography over a TALON
Superﬂow resin using conditions recommended by the manufacturer
(BD Biosciences). Fractions containing IFS were dialyzed against
buffer containing 20 mM Tris-HCl (pH 8.5) and subjected to
chromatography over a Resource Q ion exchange column (Amersham
Biosciences) using a linear NaCl gradient (0 to 500 mM) to elute IFS.
Fractions were analyzed by SDS-PAGE, and those fractions contain-
ing greater than 95% SPN were pooled (see Figure 10).
Molecular weight estimates. Size exclusion chromatography was
used to estimate the molecular weights of SPN, IFS, and the SPN-IFS
complex. All chromatography was performed on a Superdex 75 HR
10/30 column (Amersham Biosciences) using a ﬂow rate of 0.3 ml/min.
Low-molecular-weight protein standards (Amersham Biosciences, see
Figure 9) and test samples were equilibrated and developed in a buffer
of 20 mM Tris (pH 8.5) plus 100 mM NaCl. Standards were analyzed
(200 ll) on three separate occasions, and the average elution volumes
were recorded. The value of Kav was determined for each standard
using the equation Kav ¼ (Ve   Vo)/(Vt   Vo), where Ve is the elution
volume, Vo is the void volume (7.9 ml), and Vt is the bed volume of the
column (24 ml). For each standard, Kav was plotted against log Mr
(molecular weight). Molecular weight estimates represented the
average derived from at least three independent experiments.
Stoichiometry of the SPN-IFS complex. The protein concentration
of the SPN-IFS complex isolated by size exclusion chromatography
(see above) was determined using the bicinchoninic acid assay (Sigma)
and a BSA protein standard (Sigma). Various concentrations of the
complex were subjected to SDS-PAGE along with known concen-
trations of puriﬁed SPN and IFS. Gels were stained with Coomassie R-
250, and an image captured on Kodak Image Station 2000MM was
analyzed using Kodak 1D Image Analysis Software. Total pixel
intensities of each band were obtained using the ROI (region of
interest) function of the software. The intensities of bands from the
known molar concentrations of SPN and IFS included on each gel
were used to generate standard curves that were used to calculate the
concentration of SPN and IFS from the pixel intensities of bands
resolved from the complex. The calculated molar ratio reported was
based on two independent experiments, each of which yielded an
identical result.
Kinetic analysis of the inhibitory mechanism of IFS. The inhibition
mechanism of IFS was determined in kinetic assays of SPN activ-
ity monitored by ﬂuorescence detection of hydrolysis of b-NAD
þ
(Sigma), as previously described [8]. Brieﬂy, JRS4 cells were grown
overnight in DMEM-YE and centrifuged at 6,000 rpm for 10 min, and
collected supernatants were sterile-ﬁltered. One unit of SPN activity
was deﬁned as the activity in 1 ml of supernatant from the overnight
growth. At least three preparations of SPN were used throughout
these studies, and they yielded consistent and overlapping rates of
hydrolysis. SPN (0.125 U/ml) was incubated with varying concen-
trations of b-NAD
þ (up to 1.2 mM) in PBS at 37 8C for varying times
(up to 50 min). Reactions were quenched by the addition of 5N
NaOH, and the ﬂuorescence of residual b-NAD
þ was detected using
excitation wavelength of 380 nm and an emission wavelength of 455
nm on a Perkin-Elmer LS55B using the plate reader accessory. The
residual concentration of b-NAD
þ was calculated as previously
described [2]. Plots of the concentration of b-NAD
þ hydrolysis with
time were ﬁt to a straight line to obtain the observed velocity (vobs).
The rates of b-NAD
þ hydrolysis as a function of b-NAD
þ concen-
tration were ﬁt by the Michaelis-Menten equation to determine the
apparent Michaelis constant (Km,app) and the maximum rate (Vmax,obs)
[51]. The inhibition mechanism of IFS was determined in reactions of
varying concentrations of puriﬁed IFS (up to 2.3 nM) with SPN (0.125
U/ml) and varying concentrations of b-NAD
þ as described above. The
observed velocities as a function of b-NAD
þ and varying concen-
trations of IFS were simultaneously ﬁt by competitive, noncompeti-
tive, and uncompetitive inhibition models to determine the apparent
inhibition constant (KI,app), the apparent Michaelis constant (Km,app),
and the observed maximal velocity (Vmax,obs) [51]. The model that gave
the best ﬁt was used in determination of the inhibition mechanism.
Nonlinear least-squares analysis was performed with Scientist (Micro-
math, Salt Lake City, Utah, United States). Errors in the reported
parameters are 62 SDs.
Supporting Information
Table S1. Primers Used in This Study
Found at DOI: 10.1371/journal.ppat.0010035.st001 (31 KB PDF).
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Immunity Factor for SPN (IFS)Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank) accession num-
bers for the genes and gene products discussed in this paper are IFS
(DQ093072), Spy_M30129 (NC_004070), Spy_M180164
(NC_003485), spy0166 (NC_002737), strain HSC5 (DQ093073), and
strain JRS4 (DQ093072).
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